D-0111-2027 Class II Ongoing

Recalled by Brandywine Pharmaceuticals, LLC — West Chester, PA

FDA drug recall D-0111-2027 was initiated by Brandywine Pharmaceuticals, LLC on Oct 6, 2026 and is designated Class II. Reason for recall: CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory The recall status is ongoing. Affected quantity: 1,332 100-count bottles.

Recall details

Product Type
Drugs
Report Date
Nov 4, 2026
Initiation Date
Oct 6, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1,332 100-count bottles

Product description

Theophylline Extended-Release Tablets, 200 mg, Rx Only, 100-count bottle, Distributed by: Brandywine Pharmaceuticals, LLC, West Chester, PA 19382, NDC: 71321-501-10.

Reason for recall

CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory

Distribution pattern

Nationwide within U.S

Code information

Lot: 405620, Expiry: 03/31/2028.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0111-2027
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0111-2027. Report a data issue: hello@regdatalab.com.